640
Views
28
CrossRef citations to date
0
Altmetric
Review

TransMabs: cell-penetrating antibodies, the next generation

, , , &
Pages 237-241 | Published online: 20 Apr 2005

Bibliography

  • KOHLER H, PAUL S: Superantibody activities: new players in innate and adaptive immune responses. Immunol Today (1998) 19:221–227.
  • KOHLER H: Superantibodies: synergy of innate and acquired immunity. And Biochem. Biotechnol (2000) 83:1-9,145–153.
  • ZHAO Y, LOUD, BURKETT J, KOHLER H: Enhanced anti-B-cell tumor effects with anti-CD20 SuperAntibody. J. Immunother. (2002) 25:57–62.
  • ZHAO Y, KOHLER H: Enhancing tumor targeting and apoptosis using non-covalent antibody homo-dimers. j Immunother. (2002) 25:396–404.
  • AVRAMEAS A, TERNYNCK T, NATO F, BUTTIN G, AVRAMEAS S: Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules. Proc. Nail. Acad. Sci. USA (1998) 95:5601–5606.
  • UN YZ, YAO SY, VEACH RA, TORGERSON TR, HAWIGER J: Inhibition of nuclear translocation of transcription factor NF-kB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. (1995) 270:14255–14260.
  • ROJAS M, DONAHUE JP, TAN Z, LIN YZ: Genetic engineering of proteins with cell membrane permeability. Nat. Biotech. (1998) 16:370–374.
  • ZHAO Y, LOUD, BURKETT J, KOHLER H: Chemical Engineering of cell penetrating antibodies. J. Immunol Methods (2001) 254:137–145.
  • ••Provided the proof-of-concept studies ofTransMabs: cell-penetrating antibodies.
  • ZHAO Y, BROWN TL, KOHLER H, MULLER S: MTS-conjugated antiactive caspase 3 antibodies inhibit actinomycinD-induced apoptosis. Apoptosis (2003) 8:631–637.
  • ••Provided the functional studiesof TransMabs.
  • GOTTSCHALK AR, QUINTANS J: Apoptosis in B lymphocytes: the WEHI-231perspective. Immunol Cell Biol. (1995) 73:8–16.
  • CAIN K, INAYAT-HUSSAIN H, COUET C, QIN HM, OBERHAMMER FA: A novel method for detecting apoptosis shows that hepatocytes undergo a time dependent increase in DNA cleavage and chromatin condensation which is augmented after TGF-betal treatment. Biochem. J. (1996) 314:27–32.
  • BROWN TL, PATIL S, HOWE PH: Analysis of TGFB-inducible apoptosis. Methods MoL Biol. (2000) 142:149–167.
  • SCHUSTER N, KRIEGLSTEIN K: Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res. (2002) 307:1–14.
  • BROWN LT, PATIL S, CIANCI CD et al.: TGF -beta induces caspase 3-independent cleavage of alpha-II-spectrin coincident with apoptosis. j Biol. Chem. (1999) 274:23256–23262.
  • •Provided evidence of the action of active caspase-3.
  • CASERTA TM, SMITH AN, GULITICE AD, REEDY MA, BROWN TL: Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis (2003) 8:345–352.
  • VAN NOORDEN CJ: The history of Z-VAD-FMK, a tool or understanding the significance of caspase inhibition. Acta Histochem. (2001) 103:241–251.
  • SCHOTTE P, DECLERCQ W, VAN HUFFEL S, VANDENABEELE P, BEYAERT R: Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett. (1999) 442:117–121.
  • CHEN M, ONA VO, LI M, FERRANTE RJ et al.: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nat. Med. (2000) 6:797–801.
  • NISHIMOTO N, YOSHIZAKI K, MAEDA K et al.: Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol (2003) 30:1426–1435.
  • MILES DW: Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. Breast Cancer Res. (2001) 3:380–384.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.